Cbd/tch latest studies :

Latest studies about cbd /tch coming from Israel :

« Paediatrics

Two trials on spasticity in paediatrics patients suffering from cerebral palsy are in final stages, the first is a double blind, placebo control trial assessing safety and efficacy of Sativex® in 72 patients (NCT01898520, GW Research Ltd.), and the second is a randomized controlled trial comparing two cannabis oil formulations (5% CBD and 0.2% THC) and (5% CBD and 0.8% THC) provided by Tikun Olam Ltd in 40 patients (NCT02470325). In an intermediate analysis on 25 patients, adverse effects were rare and included worsening of seizures in 2 patients, behavioral changes in 2 and somnolence in 1 35. A large double blind, randomized, placebo‐controlled trial with crossover that is now recruiting, is assessing the safety, tolerability and efficacy of whole plant extract versus 99% CBD oil and placebo (provided by BOL pharma ltd) in 120 patients with autism spectrum disorder (NCT02956226). »

You can read about others conditions studed :

https://europepmc.org/article/PMC/6177696

« While some of the public and mainstream media have already accepted medical cannabis to be effective in a lengthy list of conditions, clinical studies with an appropriate study design are few. Only few studies are prospective and most clinical trials investigating medical cannabis and its derivatives are not placebo controlled, not blinded and have small sample sizes. This situation leads to a division within the medical community: those in favor of using cannabis who also usually see themselves as pioneers in this area and tend to prescribe cannabis even when the evidence is insufficient, while opponents of medical cannabis might perhaps end up denying a patient cannabis even in situations where cannabis has been shown to be beneficial (pain, nausea and sleep disturbance, National Academies of Sciences Engineering and Medicine Report 38). Furthermore, rapidly developing clinical research is rather not focused, and many cannabis research programmes are concentrated around rare diseases, where the regulatory process and thus time to marketing are perceived to be shorter. Yet, we believe that cannabis derived medications should have a significant role in the treatment of chronic pain symptoms and to be a safer substitute for opioids in palliative care.

Israel has developed a regulatory environment where the indications for which cannabis can be prescribed are tightly regulated, and developed based on the accumulation of research and clinical experience data thus far. «